"Haifeng Biomedical" activates factor 10 direct inhibitors - Taiwan Registration fb438ab203431bfd18ffee1ea94b6722
Access comprehensive regulatory information for "Haifeng Biomedical" activates factor 10 direct inhibitors in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number fb438ab203431bfd18ffee1ea94b6722 and manufactured by HYPHEN BioMed. The authorized representative in Taiwan is SYSMEX TAIWAN CO., LTD..
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Device Details
Product Details
The concentration of direct inhibitor of activated factor 10 (DiXaI) in human plasma after citrate treatment was quantitatively detected in vitro by anti-activated factor 10 colorimetric method by automated method. This product can be used to assist in the diagnosis of anticoagulant status in patients treated with oral anticoagulants (Apixaban, Rivaroxaban and Edoxaban).
B Hematology, pathology, and genetics
B.7525 Heparin analysis
Input;; QMS/QSD
Dates and Status
Dec 25, 2023
Dec 25, 2028